title: Too much ara-C? Not enough daunorubicin?
abstract: It seems strange, but after 40 years of experience using cytosine arabinoside (ara-C) and daunorubicin, leukemia doctors are still unsure as to how much of each drug they should use to treat their patients with acute myeloid leukemia (AML).
authors.affiliation: Weill-Cornell Medical College.
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Feldman